Quanterix Announces Simoa® Success Grant Program to Accelerate Promising Infectious Disease & Immunology Research
Grants will award researchers seeking to harness biomarkers to improve diagnosis, prognosis or treatment efficacy studies with access to Quanterix’ ultra-sensitive detection solutions
“We’ve always believed that innovation comes through collaboration and in uniting with the
Special consideration will be given to projects aimed at demonstrating a need for highly sensitive and specific protein detection to advance research related to the diagnosis, prognosis or treatment of diseases engaging the immune system. Applicants are encouraged to present a plan for sample analysis with Simoa® Assay Kits or a plan for development of a novel Simoa® assay utilizing the Quanterix SP-X® Imaging and Analysis System, a complete benchtop biomarker detection platform that offers true multiplex detection at both acute and baseline levels, and custom Simoa® Homebrew assay kits. As many as 130 samples may be submitted for analysis with one assay kit, or up to 65 samples may be submitted for analysis with two assay kits. All samples must be collected and stored by the applicant’s laboratory.
Upon the conclusion of the call for proposals, a
-
Grant Proposal 1:
- One proposal will be awarded a placement of a Quanterix SP-X® Instrument, Simoa® Microplate Washer, and Simoa® Microplate Shaker, plus all necessary assay kits and consumables to run the proposed study. Awardee will be trained by a Quanterix Field Application Scientist and supported through completion of the study. Should the awardee commit to additional projects utilizing Simoa® assay kits, the instrument placement will be permanent.
-
Four proposals will be awarded free of charge sample analysis at Quanterix’ in-house, state-of-the-art CLIA certified Simoa®
Accelerator Laboratory to complete the proposed study.
-
Grant Proposal 2: Two proposals will be awarded free of charge novel assay prototyping and sample analysis demonstrating proof of concept for use of the assay to achieve specific research goals. Awardee will provide antibodies, antigen and samples to
Quanterix . Work will be completed atQuanterix headquarters, and all details of assay design will be shared with the awardee to enable future work based on the study.
Validated by more than 650 peer-reviewed publications,
The grant is the latest installment in the company’s Grant Program. Established in 2016, the program has recognized innovative researchers across the country, including
This year’s recipients will be invited to present their findings of the grant-awarded research at Quanterix’ Simoa® Success Seminars Series in the Fall of 2020. This ongoing series aims to provide customers, partners and prospects with the latest Simoa® assay developments and platform applications.
To be considered for the grant, all interested parties must submit their proposals by
Additional terms and conditions apply. To learn more and submit your Simoa® Success Grant Program proposal, click here.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200424005570/en/
Media Contact:
quanterix@pancomm.com
Investor Relations Contact:
(774) 278-0496
shrusovsky@quanterix.com
Source: